ECSP16067163A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
ECSP16067163A
ECSP16067163A ECIEPI201667163A ECPI201667163A ECSP16067163A EC SP16067163 A ECSP16067163 A EC SP16067163A EC IEPI201667163 A ECIEPI201667163 A EC IEPI201667163A EC PI201667163 A ECPI201667163 A EC PI201667163A EC SP16067163 A ECSP16067163 A EC SP16067163A
Authority
EC
Ecuador
Prior art keywords
compound
heterocyclic compound
prophylaxis
obesity
medicine
Prior art date
Application number
ECIEPI201667163A
Other languages
English (en)
Inventor
Keiko Kakegawa
Yoichi Nishikawa
Zenichi Ikeda
Minoru Sasaki
Fumiaki Kikuchi
Original Assignee
Eh Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eh Europe Gmbh filed Critical Eh Europe Gmbh
Publication of ECSP16067163A publication Critical patent/ECSP16067163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona un compuesto heterocíclico fusionado que tiene una acción inhibidora de la enteropeptidasa, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc. De forma específica, se proporciona un compuesto representado por la fórmula (I) que aparece a continuación (ANEXO) en donde cada símbolo es como se lo define en la presente, o una sal de él, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc.
ECIEPI201667163A 2014-02-13 2016-08-11 Compuesto heterocíclico ECSP16067163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014025944 2014-02-13

Publications (1)

Publication Number Publication Date
ECSP16067163A true ECSP16067163A (es) 2017-10-31

Family

ID=52589730

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201667163A ECSP16067163A (es) 2014-02-13 2016-08-11 Compuesto heterocíclico

Country Status (22)

Country Link
US (2) US9428470B2 (es)
EP (1) EP3105228B1 (es)
JP (1) JP6458054B2 (es)
KR (1) KR20160113299A (es)
CN (1) CN106170487A (es)
AR (1) AR099399A1 (es)
AU (1) AU2015216439A1 (es)
BR (1) BR112016018548A2 (es)
CA (1) CA2939675A1 (es)
CL (1) CL2016002023A1 (es)
CR (1) CR20160368A (es)
EA (1) EA201691624A1 (es)
EC (1) ECSP16067163A (es)
IL (1) IL247018A0 (es)
MA (1) MA39247B1 (es)
MX (1) MX2016010561A (es)
PE (1) PE20161396A1 (es)
PH (1) PH12016501614A1 (es)
SG (1) SG11201606176YA (es)
TW (1) TW201609677A (es)
UY (1) UY35995A (es)
WO (1) WO2015122188A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194604A (en) 2013-03-13 2022-12-06 Takeda Pharmaceuticals Co Guanidinobenzoic acid ester compound
CR20200199A (es) 2014-02-13 2020-06-19 Incyte Corp CICLOPROPILAMINA COMO INHIBIDOR DE LA LSD1 (Divisional 2016-0396)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP3105226B1 (en) 2014-02-13 2019-09-04 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
US10017487B2 (en) 2015-03-27 2018-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
AU2018361589A1 (en) 2017-11-02 2020-06-04 Ube Corporation Double-headed protease inhibitor
KR102325422B1 (ko) 2018-05-09 2021-11-11 주식회사 엘지화학 엔테로펩티다아제 억제 활성을 나타내는 신규 화합물
US20210403420A1 (en) * 2018-08-27 2021-12-30 Scohia Pharma, Inc. Benzoate compound
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US20220281866A1 (en) 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114929246A (zh) * 2019-11-04 2022-08-19 法拉第制药公司 碘化物化合物用于治疗和预防化学疗法相关的恶病质和心脏毒性的用途
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
WO1994013631A1 (en) 1992-12-10 1994-06-23 Teikoku Chemical Industries Co., Ltd. Propionic acid derivative
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
WO1997037969A1 (fr) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Inhibiteur de tryptase derives de guanidino
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
TW200416029A (en) 2002-11-01 2004-09-01 Takeda Chemical Industries Ltd Agent for preventing or treating neuropathy
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
EP1697339A1 (en) 2003-12-25 2006-09-06 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006057152A1 (ja) 2004-11-08 2006-06-01 Ono Pharmaceutical Co., Ltd. タンパク質分解酵素阻害化合物からなる糖尿病治療剤
WO2006050999A2 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
US20080274945A1 (en) 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
GEP20115359B (en) 2006-06-27 2011-12-26 Takeda Pharmaceutical Fused cyclic compounds
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
ME00681B (me) 2006-10-19 2011-12-20 Takeda Pharmaceuticals Co Jedinjenje indola
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
ES2532201T3 (es) 2009-12-07 2015-03-25 Ajinomoto Co., Inc. Derivado de éster de ácido heteroarilcarboxílico
ES2618024T3 (es) 2011-06-07 2017-06-20 Ea Pharma Co., Ltd. Derivado de éster de ácido carboxílico heterocíclico
CA2848561C (en) 2011-09-15 2019-04-02 Astellas Pharma Inc. Guanidinobenzoic acid compound
CN108904810A (zh) 2012-01-03 2018-11-30 奥拉姆德有限公司 治疗糖尿病的方法和组合物
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
CA2903215C (en) 2013-03-08 2021-07-20 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
MY194604A (en) 2013-03-13 2022-12-06 Takeda Pharmaceuticals Co Guanidinobenzoic acid ester compound
ES2773250T3 (es) 2013-06-21 2020-07-10 Myokardia Inc Compuestos de pirimidindiona contra afecciones cardíacas
TN2016000077A1 (en) 2013-09-16 2017-07-05 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
CR20200199A (es) 2014-02-13 2020-06-19 Incyte Corp CICLOPROPILAMINA COMO INHIBIDOR DE LA LSD1 (Divisional 2016-0396)
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3105226B1 (en) 2014-02-13 2019-09-04 Incyte Corporation Cyclopropylamines as lsd1 inhibitors

Also Published As

Publication number Publication date
CL2016002023A1 (es) 2017-03-24
CR20160368A (es) 2016-12-01
EP3105228B1 (en) 2018-09-26
JP2017505823A (ja) 2017-02-23
US10023544B2 (en) 2018-07-17
CN106170487A (zh) 2016-11-30
SG11201606176YA (en) 2016-08-30
EP3105228A1 (en) 2016-12-21
MX2016010561A (es) 2016-11-16
AU2015216439A1 (en) 2016-08-11
UY35995A (es) 2015-08-31
IL247018A0 (en) 2016-09-29
EA201691624A1 (ru) 2017-05-31
CA2939675A1 (en) 2015-08-20
AR099399A1 (es) 2016-07-20
KR20160113299A (ko) 2016-09-28
US9428470B2 (en) 2016-08-30
US20150225354A1 (en) 2015-08-13
TW201609677A (zh) 2016-03-16
US20160347724A1 (en) 2016-12-01
BR112016018548A2 (pt) 2019-01-15
WO2015122188A1 (en) 2015-08-20
JP6458054B2 (ja) 2019-01-23
PE20161396A1 (es) 2017-01-10
PH12016501614A1 (en) 2017-02-06
MA39247A1 (fr) 2017-11-30
MA39247B1 (fr) 2018-04-30

Similar Documents

Publication Publication Date Title
ECSP16067163A (es) Compuesto heterocíclico
ECSP16067137A (es) Compuesto heterocíclico fusionado
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
UY36199A (es) Compuesto heterocíclico
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
UY35821A (es) Compuesto heterocíclico
CR20120448A (es) Compuesto heterocíclico
UY35774A (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
CO2017003699A2 (es) Compuesto heterocíclico
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
UY35650A (es) Compuesto heterocíclico
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
ES1160087Y (es) Regulador de aspiracion aplicable a aspiradores quirurgicos.
TH1501007273A (th) การปรับปรุงให้ดีขึ้นใน หรือ ความสัมพันธ์กับสารประกอบอินทรีย์
ITUB20153315A1 (it) Maniglia per serrature, particolarmente di tipo antipanico.
UA30404S (uk) Пляшка «царское село»
TH1601002306A (th) ชุดประกอบกุญแจแบบล็อกด้วยเดือยสำหรับการใช้กับแคมทรงกระบอกในเขตสามเขต
UA102145U (uk) Пристосування для захисту від поранень
CL2011001917A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico.